Connect with us

Hi, what are you looking for?

Editor's Pick

‘Both sides are wrong’: Longtime Obamacare critic says GOP is mistaken in shutdown struggle

In the view of Avik Roy — one of the first and most vocal critics of the Affordable Care Act (ACA), also known as Obamacare — Republicans and Democrats alike have missed the mark in the healthcare debate that has dragged the government into a 24-day shutdown.

‘Both sides are wrong,’ Avik said. ‘I’m sympathetic to the Republican view, but it’s a strategic mistake.’

The way Roy sees things, Republican wariness over renewing expanded government subsidies should be directed at the bigger problem behind them.

‘The subsidies aren’t inherently the problem,’ Roy said. ‘If you want low-income people who are near the poverty line to have insurance, you’re going to have to subsidize. Subsidies have been a part of Republican [healthcare] plans and Democratic plans. I would argue that the approach to subsidies that Obamacare used was actually pretty reasonable.’

That doesn’t mean he believes the government’s current healthcare trajectory is sustainable, either.

The federal government entered a 24-day shutdown at the beginning of October when lawmakers failed to come to an agreement over spending legislation to begin the new fiscal year. Republicans advanced a short-term spending bill that would have bought more time for lawmakers to finalize funding for 2026. But Democrats, led by Senate Minority Leader Chuck Schumer, D-N.Y., and House Minority Leader Hakeem Jeffries, D-N.Y., have shot down that measure repeatedly, demanding that Congress first address expiring COVID-era insurance subsidies.

As a part of its American Rescue Plan, the Biden administration greatly widened the pool of eligible applicants who could receive a federal subsidy to help pay for their Obamacare health insurance.

In its original form, Obamacare capped subsidies for anyone making over 400% of the federal poverty level. But that changed in 2021 when, as an emergency response to COVID-19, Congress temporarily removed that cap.

The cap will go back into effect at the end of 2025.

Findings by KFF, a healthcare policy think tank, indicate that over 90% of the 24 million Obamacare enrollees make use of the expanded credits. Letting them expire could leave those Obamacare enrollees suddenly footing a substantially heftier bill. But, according to the Committee of a Responsible Federal Budget, a nonpartisan fiscal policy think tank, continuing the policy would also come with a steep price tag; upwards of $30 billion annually.

Republicans — especially the Hill’s most fiscally conservative lawmakers — have called for the subsidies to expire to help reel the country’s spending back under control.

Despite agreeing with Republicans that Obamacare did little to make health insurance more affordable, Roy believes Republican insistence on letting them expire won’t solve Obamacare’s underlying problems that are driving prices higher: regulations.

Roy believes Republicans should use the moment to negotiate, extending the subsidies for maybe one to two years for existing enrollees in exchange for a permanent fix of the costliest Obamacare regulations driving costs upward.

‘In Switzerland [health insurance] costs $200 a month or $300 a month. The same plan in America costs $1,000 a month or $15,000 a month. Subsidizing it also costs a lot. But having a scale where the subsidy fades out gradually as you go up the income scale — that part is fine.’

Roy praised efforts from the Trump administration to bring the underlying costs of healthcare down, most recently through the most favored nation strategy. Under that plan, the Trump administration had leveraged the price other countries pay for pharmaceuticals to bring U.S. prices down.

In theory, the most favored nation plan would set American prices at the lowest rates other countries pay.

‘They’re not actually deals that truly establish most favored nation status because it’s company by company, and they are on particular drugs. But the general idea — if you want to participate in the U.S. market you’ve got to give us the lowest price you give any other advanced economy — I think that’s eminently reasonable,’ Roy said of the administration’s negotiations.

In response to Democratic demands, Republicans in Congress maintain that the enhanced premium tax credits are completely unrelated to the government’s funding and rejected those demands out of hand.

The Senate has voted on a short-term funding bill 12 times since the beginning of the shutdown and appeared no closer to finding a resolution when the lawmakers left town on Thursday.

The Senate will return to Washington, D.C., at the beginning of next week.

This post appeared first on FOX NEWS

    Sign up and get the scoop before anyone else—fresh updates, and secret deals, all wrapped up just for you. We're talking juicy tips, fun surprises, and invites to events you actually want to go to. Don’t just watch from the sidelines—jump in and be part of the magic!


    By signing up, you're cool with getting emails from us. Don’t worry—your info stays safe, sound, and strictly confidential. No spam, no funny business. Just the good stuff.

    You May Also Like

    Investing

    Fisker (NYSE: FSR) stock price has been one of the best-performing electric vehicle (EV) stocks this week even as Tesla slumped. The shares jumped...

    Investing

    Newmont (NYSE: NEM) reported mixed financial results even as the price of gold approached its all-time high. In all, the company’s earnings per share...

    Investing

    The Fox Corporation (NASDAQ: FOX) stock price has been under pressure as investors come to terms with the abrupt firing of Tucker Carlson. The...

    Investing

    NatWest (LON: NWG) share price rose sharply, helped by the strong results from Barclays. The stock jumped to a high of 274.8p, which was...




    Disclaimer: Oldamericanbroker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the-company.


    Copyright © 2025 Oldamericanbroker.com